A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT06863272
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about: The safety of the study treatment and if people tolerate it. A safe dose level of I-DXd that can be used with other treatments. Participant levels of prostate specific antigen (PSA) during treatment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Castration-Resistant Prostatic Cancer
- Metastasis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Merck Sharp & Dohme LLC
- Last updated on ClinicalTrials.gov
- October 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- UCLA Hematology & Oncology ( Site 0003) · Los Angeles, CA
- University of California-Irvine Medical Center ( Site 0016) · Orange, CA
- UCSF Medical Center at Mission Bay ( Site 0034) · San Francisco, CA
District of Columbia · 1
- MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026) · Washington D.C., DC
Michigan · 1
- University of Michigan ( Site 0021) · Ann Arbor, MI
New York · 1
- Memorial Sloan Kettering Cancer Center ( Site 0006) · New York, NY
Pennsylvania · 1
- UPMC Hillman Cancer Center ( Site 0014) · Pittsburgh, PA
Tennessee · 1
- The West Clinic, PLLC dba West Cancer Center ( Site 0005) · Germantown, TN
Washington · 1
- Fred Hutchinson Cancer Center ( Site 0013) · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.